What is the correct management of stage i UPSC?

UPSC has been identified as a distinct variant of endometrial cancer and it has been reported to be associated with more aggressive behavior and a worse prognosis compared to endometrioid adenocarcinomas of the endometrium. Various studies have demonstrated survival rates of 15–51% for clinical stage I disease and 35–90% for surgical stage I/II disease. Aside from the very limited number of studies that incorporate comprehensive surgical staging, the majority of these reports used clinical parameters for staging or very limited surgical staging techniques and information.
A significant amount of controversy surrounds the optimal management of patients with stage I UPSC, and appropriate management of these patients has yet to be firmly established. The low incidence of this particular type of cancer, the variety of surgical interventions, and the wide variety of post-operative adjuvant therapies have made it extremely difficult to identify the optimal management of patients with UPSC. Prior to 2004, adjuvant treatment recommendations for surgical stage I UPSC were largely based on very small retrospective patient series (<20 patients), only a fraction of which included surgically staged patients. A recent publication reported the outcomes of surgical stage I UPSC patients from four institutions ⁽¹⁾ . Recurrence rates were lower than that published in previous studies, suggesting a potential benefit of comprehensive surgical staging in these patients. The risk of recurrence and mean overall survival were similar between surgical stage I UPSC patients who were managed conservatively versus those treated with adjuvant radiation therapy. Moreover, this study also suggests a potential benefit of adjuvant chemotherapy in these patients.